AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 287: E82-E89, 2004. First published March 9, 2004; doi:10.1152/ajpendo.00494.2003
0193-1849/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/1/E82    most recent
00494.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (50)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tietge, U. J. F.
Right arrow Articles by Bahr, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tietge, U. J. F.
Right arrow Articles by Bahr, M. J.

Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics

Uwe J. F. Tietge,1,2 Klaus H. W. Böker,1 Michael P. Manns,1 and Matthias J. Bahr1

1Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, D-30625 Hannover; and 2Department of Medicine, Humboldt University, Charité Campus Mitte, D-10117 Berlin, Germany

Submitted 3 November 2003 ; accepted in final form 2 March 2004

Adiponectin is a novel adipocytokine negatively correlated with parameters of the metabolic syndrome, such as body mass index (BMI), body fat mass (BFM), and circulating insulin levels. Furthermore, metabolic actions directly on the liver have been described. The aim of the present study was to characterize circulating adiponectin levels, hepatic turnover, and the association of adiponectin with key parameters of hepatic as well as systemic metabolism in cirrhosis, a catabolic disease. Circulating adiponectin levels and hepatic turnover were investigated in 20 patients with advanced cirrhosis. Hepatic hemodynamics [portal pressure, liver blood flow, hepatic vascular resistance, indocyanine green (ICG) half-life], body composition, resting energy expenditure, hepatic free fatty acids (FFA) and glucose turnover, and circulating levels of hormones (catecholamines, insulin, glucagon) and proinflammatory cytokines (IL-1{beta}, TNF-{alpha}, IL-6) were also assessed. Circulating adiponectin increased dependently on the clinical stage in cirrhosis compared with controls (15.2 ± 1.7 vs. 8.2 ± 1.1 µg/ml, respectively, P < 0.01), whereas hepatic extraction decreased. Adiponectin was negatively correlated with parameters of hepatic protein synthesis (prothrombin time: r = –0.62, P = 0.003; albumin: r = –0.72, P < 0.001) but not with transaminases or parameters of lipid metabolism. In addition, circulating adiponectin increased with portal pressure (r = 0.67, P = 0.003), hepatic vascular resistance (r = 0.60, P = 0.008), and effective hepatic blood flow (ICG half-life: r = 0.69, P = 0.001). Adiponectin in cirrhosis was not correlated with BMI, BFM, parameters of energy metabolism, insulin levels, hepatic FFA and glucose turnover, and circulating proinflammatory cytokines. These results demonstrate that 1) adiponectin plasma levels in cirrhosis are significantly elevated, 2) the liver is a major source of adiponectin extraction, and 3) adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism but exclusively with reduced liver function and altered hepatic hemodynamics.

hepatic turnover; hepatic venous pressure gradient; calorimetry; body composition



Address for reprint requests and other correspondence: U. Tietge, Dept. of Medicine, NWFZ, 5. Ebene, Charité Campus Mitte, Schumannstr. 20/21, D-10117 Berlin, Germany (E-mail: u_tietge{at}yahoo.com).




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
T. Bose, V. S. Voruganti, M. E. Tejero, J. M. Proffitt, L. A. Cox, J. L. VandeBerg, M. C. Mahaney, J. Rogers, J. H. Freeland-Graves, S. A. Cole, et al.
Quantitative Loci Regulating Plasma Levels of {gamma} Glutamyl Transferase and Albumin and Their Genetic Correlations with Cardiovascular Risk Factors
Experimental Biology and Medicine, December 1, 2009; 234(12): 1519 - 1524.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. F. de Boer, M. J. Bahr, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis
Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G196 - G201.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. J. Bahr, J. Ockenga, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge
Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E199 - E206.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
Y. Nakano, S. Tajima, A. Yoshimi, H. Akiyama, M. Tsushima, T. Tanioka, T. Negoro, M. Tomita, and T. Tobe
A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin
J. Lipid Res., July 1, 2006; 47(7): 1572 - 1582.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
C. Pagano, G. Soardo, W. Esposito, F. Fallo, L. Basan, D. Donnini, G. Federspil, L. A Sechi, and R. Vettor
Plasma adiponectin is decreased in nonalcoholic fatty liver disease
Eur. J. Endocrinol., January 1, 2005; 152(1): 113 - 118.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.